Charles River Laboratories (CRL)
Provider of research models, nonclinical drug-development services, and manufacturing quality-control testing.
Something off on this page? Send us feedback.
Sells research models and related services, performs outsourced discovery and regulated nonclinical safety studies, and supplies microbial and biologics quality-control testing. Most revenue comes from services, with the portfolio now refocused on regulated testing after divesting CDMO, Cell Solutions, and selected European discovery operations.
Supplies research models and related services, runs outsourced discovery and safety studies, and provides manufacturing quality-control testing across its reporting segments: Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions. The latter houses Microbial Solutions and Biologics Testing Solutions following recent divestitures of CDMO, Cell Solutions, and selected European discovery sites.
Serves pharmaceutical and biotechnology companies, government agencies, hospitals, and academic institutions through operations spanning North America, Europe, and Asia. Controlled model production, animal-health monitoring, regulated study execution, bioanalysis, and microbial and biologics testing let clients outsource work from early discovery through nonclinical development and product release.
Animal-welfare and laboratory regulations govern much of the work, while safety-assessment capacity depends partly on a compliant, timely supply of non-human primates.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 17, 2026 | Argus Research | Target | Target: $200 | Target: $330 |
| Sep 11, 2026 | Evercore ISI | Reiterate | Rating: —Target: $220 | Target: $320 |
| Aug 10, 2026 | Piper Sandler | Target | Target: — | Target: $300 |
| Aug 10, 2026 | Mizuho Securities | Target | Target: $230 | Target: $264 |
| Aug 7, 2026 | Morgan Stanley | Reiterate | Rating: —Target: $260 | Target: $300 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 27, 2026Cash & short-term investments $192.0M · Total debt $3.03B · Total assets $7.53B · Shareholders' equity $2.84B
- Revenue
- $1.00B
- Operating income
- $119.9M
- Net income
- −$1.5M
No dividends on record.
| Institutions | 120.05% | 57.31M shares | |
|---|---|---|---|
| 584 holders · as of Jun 30, 2026 | |||
| Insiders | 1.10% | 524.3K shares | |
| 22 holders · as of Aug 27, 2026 | |||
| Adds to | 121.15% | ||
47.74M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 121.15%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
FMR LLCInstitution | 8.88% | 4.24M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 7.96% | 3.80M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 6.60% | 3.15M | as of Jun 30, 2026 |
Invesco Ltd.Institution | 6.25% | 2.98M | as of Jun 30, 2026 |
Harris Associates L PInstitution | 4.69% | 2.24M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 25, 2026 | James C. Foster | director | −33,561 | $300.00 |
| Aug 19, 2026 | Shannon M. Parisotto | officer: CEVP, Disc & Safety Assessment | −2,039 | $294.12 |
| Aug 18, 2026 | Nancy C. Andrews | director | −573 | $285.24 |
| Aug 11, 2026 | Shannon M. Parisotto | officer: CEVP, Disc & Safety Assessment | −3,714 | $279.66 |
| Aug 11, 2026 | Birgit Girshick | director, officer: Chief Executive Officer | −6,500 | $279.90 |
- Labcorp
Central labs and nonclinical services overlap CRL's DSA workflow.
- Thermo Fisher Scientific
Broad overlap in CRO, lab services, instruments, and microbiology QC.
- IQVIA
Clinical, lab, and discovery-services overlap around biopharma R&D.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Charles River Laboratories | $289.34 | +3.70% | $13.44B | — | 23.5 | 3.4 | −2.7% |
| Labcorp | $314.28 | −2.09% | $26.32B | 26.6 | 16.6 | 1.8 | +5.8% |
| Thermo Fisher Scientific | $658.54 | −0.03% | $244.81B | 35.4 | 25.1 | 5.3 | +10.5% |
| IQVIA | $270.92 | +0.39% | $44.42B | 33.5 | 19.9 | 2.6 | +8.7% |
| Median | 33.5 | 19.9 | 2.6 | +8.7% |